Profile data is unavailable for this security.
About the company
Novoprotein Scientific Inc is a China-based company mainly engaged in the provision of recombinant protein application solutions. The Company is mainly engaged in the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents, and the provision of related technical services. The Company's main products include novel coronavirus diagnostic antibodies, novel coronavirus diagnostic antigens, novel coronavirus pseudoviruses, novel coronavirus non-structural proteins and messenger ribonucleic acid (mRNA) raw materials enzymes and reagents. Its products and services are mainly used in biological medicine, basic research of life science, in vitro diagnosis, mRNA vaccine drugs and other fields. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)136.28m
- Net income in CNY-927.60k
- Incorporated2009
- Employees579.00
- LocationNovoprotein Scientific IncNo.12 Kechuang ParkNo.2358 Chang'an Road, Wujiang DistrictSUZHOU 215299ChinaCHN
- Phone+86 51 263919116
- Fax+86 51 263917398
- Websitehttps://www.novoprotein.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hanshang Group Co Ltd | 1.36bn | 49.62m | 2.45bn | 2.38k | 48.74 | 1.42 | -- | 1.80 | 0.1707 | 0.1707 | 4.65 | 5.84 | 0.3705 | 2.75 | 8.35 | 573,421.20 | 1.16 | 2.00 | 1.92 | 3.89 | 58.35 | 57.24 | 3.13 | 4.89 | 0.3366 | 2.15 | 0.3198 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
| Jiangsu Cowin Biotech Co Ltd | 123.20m | -117.37m | 2.48bn | 657.00 | -- | 1.52 | -- | 20.11 | -1.12 | -1.12 | 1.21 | 14.49 | 0.0664 | 1.33 | 1.23 | 187,520.90 | -6.63 | -- | -6.94 | -- | 58.15 | -- | -99.82 | -- | 14.37 | -- | 0.0184 | -- | -67.15 | -- | -153.00 | -- | -- | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 676.85m | 155.83m | 2.50bn | 738.00 | 15.96 | 2.04 | -- | 3.69 | 0.4781 | 0.4781 | 2.07 | 3.74 | 0.3666 | 1.92 | 11.71 | 917,147.40 | 8.40 | 12.01 | 10.14 | 14.75 | 63.88 | 69.79 | 22.92 | 22.84 | 1.21 | -- | 0.2589 | 36.44 | 2.54 | 4.24 | 0.8129 | 10.94 | -23.56 | 12.84 |
| Novoprotein Scientific Inc | 136.28m | -927.60k | 2.52bn | 579.00 | -- | 1.15 | -- | 18.50 | -0.0132 | -0.0132 | 1.94 | 31.19 | 0.0585 | 0.4493 | 1.67 | 235,364.30 | -0.0398 | -- | -0.0409 | -- | 70.17 | -- | -0.6807 | -- | 34.49 | -- | 0.0353 | -- | -42.09 | -- | -85.84 | -- | -- | -- |
| Ginwa Enterprise Group Inc | 572.93m | -23.61m | 2.52bn | 553.00 | -- | 1.56 | -- | 4.40 | -0.0633 | -0.0633 | 1.53 | 4.32 | 0.2988 | 4.74 | 5.64 | 1,036,046.00 | -1.23 | 0.3641 | -1.44 | 0.4141 | 75.60 | 73.64 | -4.12 | 1.15 | 3.33 | 0.3439 | 0.0206 | 124.25 | -2.41 | -5.37 | -228.19 | -- | 61.66 | -- |
| Beijing Succeeder Technology Inc | 284.54m | 120.76m | 2.55bn | 296.00 | 21.09 | 1.56 | -- | 8.95 | 1.14 | 1.14 | 2.68 | 15.36 | 0.1711 | 2.39 | 9.52 | 961,290.60 | 7.26 | 7.77 | 7.63 | 8.25 | 62.48 | 61.03 | 42.43 | 38.34 | 14.58 | -- | 0.00007 | 22.22 | 20.40 | 6.60 | 12.29 | 15.57 | 99.03 | -- |
| Shanghai Fudan Forward S&T Co Ltd | 665.16m | -6.01m | 2.58bn | 1.36k | -- | 3.24 | -- | 3.88 | -0.0089 | -0.0089 | 0.9791 | 1.16 | 0.3776 | 0.6066 | 8.47 | 488,010.90 | -0.3031 | -0.8781 | -0.5073 | -1.53 | 40.85 | 43.22 | -0.8027 | -1.85 | 0.4956 | -1.83 | 0.3817 | -- | -13.86 | -7.58 | 196.17 | -32.57 | -13.88 | -- |
| Cabio Biotech Wuhan Co Ltd | 473.06m | 101.38m | 2.62bn | 508.00 | 26.23 | 1.75 | -- | 5.54 | 0.594 | 0.594 | 2.77 | 8.92 | 0.2948 | 2.49 | 2.27 | 931,222.90 | 6.01 | 7.81 | 6.55 | 8.34 | 41.34 | 46.96 | 20.40 | 28.65 | 6.19 | -- | 0.008 | 39.86 | 2.39 | 9.18 | 41.95 | -1.19 | 89.01 | -- |
Data as of May 31 2024. Currency figures normalised to Novoprotein Scientific Inc's reporting currency: Chinese Yuan Renminbi CNY
17.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Huashang Fund Management Co., Ltd.as of 31 Dec 2023 | 1.14m | 6.73% |
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 916.67k | 5.40% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 300.15k | 1.77% |
| Orient Securities Asset Management Co. Ltd.as of 31 Dec 2023 | 249.46k | 1.47% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 94.35k | 0.56% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 81.77k | 0.48% |
| Western Leadbank Fund Management Co., Ltdas of 31 Dec 2023 | 76.65k | 0.45% |
| First-Trust Fund Management Co., Ltd.as of 31 Dec 2023 | 31.09k | 0.18% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 26.91k | 0.16% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 21.45k | 0.13% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
